<p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）的股票在週一由 Wells Fargo &amp; Company 的股票研究人員在一份發給投資者的報告中重申了 “持平” 評級，Benzinga 報道。他們目前對該股票的目標價為 42.00 美元，高於之前的 35.00 美元目標價。Wells Fargo &amp; Company 的目標價表明，相較於公司之前的收盤價，潛在上漲幅度為 6.03%。</p>
<ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
<p>其他幾家研究公司也最近對 CNTA 發表了看法。Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Centessa Pharmaceuticals 股票的 “賣出（d-）” 評級。Guggenheim 在 4 月 2 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Wolfe Research 在 3 月 31 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “跑贏大盤” 下調至 “持有”。Stephens 在 3 月 31 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。最後，Leerink Partners 在 4 月 1 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “跑贏大盤” 下調至 “持有”，並將其目標價從 36.00 美元上調至 40.00 美元。四位投資分析師對該股票給予了買入評級，九位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為 40.70 美元。</p>
<p><strong>閲讀我們關於 Centessa Pharmaceuticals 的最新報告</strong></p>
<h2>Centessa Pharmaceuticals 股票表現</h2>
<p>Centessa Pharmaceuticals 的股票在週一的午盤交易中下跌 0.05 美元，達到 39.61 美元。該股票的交易量為 819,934 股，而其平均交易量為 2,431,604 股。Centessa Pharmaceuticals 的 12 個月低點為 10.95 美元，12 個月高點為 40.26 美元。該公司的 50 日移動平均價格為 30.15 美元，200 日移動平均價格為 26.76 美元。該公司的市值為 61.2 億美元，市盈率為-26.95，貝塔值為 1.25。該公司的速動比率為 8.57，流動比率為 8.57，債務與股本比率為 0.21。</p>
<p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）最後一次公佈季度財報是在 3 月 31 日。該公司報告每股收益（EPS）為-0.48 美元，低於分析師的共識預期-0.38 美元，差距為 0.10 美元。整體來看，研究分析師預測 Centessa Pharmaceuticals 在當前財政年度的每股收益為-1.6 美元。</p>
<h2>Centessa Pharmaceuticals 的內部買賣</h2>
<p>在其他 Centessa Pharmaceuticals 的新聞中，內部人士 Gregory M. Weinhoff 在 3 月 13 日的交易中出售了 73,196 股該公司的股票。該股票以平均價格 26.33 美元出售，總交易額為 1,927,250.68 美元。交易完成後，內部人士持有 65,925 股公司股票，價值約為 1,735,805.25 美元。這筆交易代表了他們持股的 52.61% 的減少。該出售在向 SEC 的備案中披露，可以通過此鏈接訪問。此外，內部人士 Iqbal J. Hussain 在 2 月 2 日的交易中出售了 38,951 股該公司的股票。這些股票以平均價格 25.15 美元出售，總價值為 979,617.65 美元。交易完成後，內部人士持有 57,645 股公司股票，價值為 1,449,771.75 美元。這筆交易代表了他們持股的 40.32% 的減少。該出售的 SEC 備案提供了更多信息。在過去 90 天內，內部人士出售了 349,073 股公司股票，價值為 9,429,412 美元。當前 7.09% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者和對沖基金最近買賣了該公司的股票。TD Waterhouse Canada Inc.在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 25,000 美元。Caitong International Asset Management Co. Ltd 在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 36,000 美元。T. Rowe Price Investment Management Inc.在第四季度將其在 Centessa Pharmaceuticals 的持股增加了 7,580.0%。T. Rowe Price Investment Management Inc.現在擁有 1,536 股該公司的股票，價值 39,000 美元，此前在上個季度又購買了 1,516 股。Wells Fargo &amp; Company MN 在第四季度將其在 Centessa Pharmaceuticals 的持股增加了 42.4%。Wells Fargo &amp; Company MN 現在擁有 3,387 股該公司的股票，價值 85,000 美元，此前在上個季度又購買了 1,008 股。最後，Knott David M Jr 在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值 100,000 美元。82.01% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Centessa Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Centessa Pharmaceuticals plc 是一家全球臨牀階段生物製藥公司，專注於在多個疾病領域發現和開發創新療法。該公司運營一個模塊化的研發網絡，將一系列獨立的專業研究實體整合在一個企業框架下。該結構旨在加速決策和資源分配，同時利用每個治療領域的深厚科學專業知識。</p>
<p>Centessa 的產品線涵蓋腫瘤學、免疫學、神經科學、心血管和代謝疾病，以及罕見遺傳疾病。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Centessa Pharmaceuticals</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
<p>在考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
<p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CNTA

<p>富國銀行（Wells Fargo & Company）重申了對 Centessa Pharmaceuticals（NASDAQ:CNTA）的 “持平” 評級，並將其目標價格從 35.00 美元上調至 42.00 美元，顯示出 6.03% 的潛在上漲空間。目前，該股票被分析師評為 “持有”，平均目標價格為 40.70 美元。最近的交易中，股票價格為 39.61 美元，12 個月的價格區間為 10.95 美元至 40.26 美元。內部交易活動顯示出顯著的銷售，內部人士持有的股份佔比為 7.09%。機構投資者近期在買賣股票方面也表現活躍</p>

<p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report)'s stock had its &#34;equal weight&#34; rating reaffirmed by equities researchers at Wells Fargo &amp; Company in a note issued to investors on Monday,Benzinga reports. They presently have a $42.00 price target on the stock, up from their prior price target of $35.00. Wells Fargo &amp; Company's price objective would indicate a potential upside of 6.03% from the company's previous close.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）的股票在週一由 Wells Fargo &amp; Company 的股票研究人員在一份發給投資者的報告中重申了 “持平” 評級，Benzinga 報道。他們目前對該股票的目標價為 42.00 美元，高於之前的 35.00 美元目標價。Wells Fargo &amp; Company 的目標價表明，相較於公司之前的收盤價，潛在上漲幅度為 6.03%。</p>
</div><ul>
<li>Wake Up to This Biotech Stock That Still Has Big Potential Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>關注這隻生物科技股票，它仍然具有巨大的潛在上漲空間</li>
</ul>
</div><p>Several other research firms have also recently weighed in on CNTA. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 21st. Guggenheim cut shares of Centessa Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, April 2nd. Wolfe Research cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Stephens cut shares of Centessa Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, March 31st. Finally, Leerink Partners cut shares of Centessa Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;hold&#34; rating and upped their price objective for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Hold&#34; and a consensus target price of $40.70.</p>
<div class="lb-trans"><p>其他幾家研究公司也最近對 CNTA 發表了看法。Weiss Ratings 在 1 月 21 日的研究報告中重申了對 Centessa Pharmaceuticals 股票的 “賣出（d-）” 評級。Guggenheim 在 4 月 2 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “買入” 下調至 “持有”。Wolfe Research 在 3 月 31 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “跑贏大盤” 下調至 “持有”。Stephens 在 3 月 31 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “強力買入” 下調至 “持有”。最後，Leerink Partners 在 4 月 1 日的研究報告中將 Centessa Pharmaceuticals 的股票評級從 “跑贏大盤” 下調至 “持有”，並將其目標價從 36.00 美元上調至 40.00 美元。四位投資分析師對該股票給予了買入評級，九位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票目前的平均評級為 “持有”，共識目標價為 40.70 美元。</p>
</div><p><strong>Read Our Latest Report on Centessa Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Centessa Pharmaceuticals 的最新報告</strong></p>
</div><h2>Centessa Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 股票表現</h2>
</div><p>Centessa Pharmaceuticals stock traded down $0.05 during midday trading on Monday, reaching $39.61. The stock had a trading volume of 819,934 shares, compared to its average volume of 2,431,604. Centessa Pharmaceuticals has a 12 month low of $10.95 and a 12 month high of $40.26. The firm's 50-day moving average price is $30.15 and its 200 day moving average price is $26.76. The firm has a market capitalization of $6.12 billion, a PE ratio of -26.95 and a beta of 1.25. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals 的股票在週一的午盤交易中下跌 0.05 美元，達到 39.61 美元。該股票的交易量為 819,934 股，而其平均交易量為 2,431,604 股。Centessa Pharmaceuticals 的 12 個月低點為 10.95 美元，12 個月高點為 40.26 美元。該公司的 50 日移動平均價格為 30.15 美元，200 日移動平均價格為 26.76 美元。該公司的市值為 61.2 億美元，市盈率為-26.95，貝塔值為 1.25。該公司的速動比率為 8.57，流動比率為 8.57，債務與股本比率為 0.21。</p>
</div><p>Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals（納斯達克代碼：CNTA - 獲取免費報告）最後一次公佈季度財報是在 3 月 31 日。該公司報告每股收益（EPS）為-0.48 美元，低於分析師的共識預期-0.38 美元，差距為 0.10 美元。整體來看，研究分析師預測 Centessa Pharmaceuticals 在當前財政年度的每股收益為-1.6 美元。</p>
</div><h2>Insider Buying and Selling at Centessa Pharmaceuticals</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 的內部買賣</h2>
</div><p>In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 73,196 shares of the firm's stock in a transaction on Friday, March 13th. The stock was sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the transaction, the insider owned 65,925 shares of the company's stock, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Iqbal J. Hussain sold 38,951 shares of the firm's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company's stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Centessa Pharmaceuticals 的新聞中，內部人士 Gregory M. Weinhoff 在 3 月 13 日的交易中出售了 73,196 股該公司的股票。該股票以平均價格 26.33 美元出售，總交易額為 1,927,250.68 美元。交易完成後，內部人士持有 65,925 股公司股票，價值約為 1,735,805.25 美元。這筆交易代表了他們持股的 52.61% 的減少。該出售在向 SEC 的備案中披露，可以通過此鏈接訪問。此外，內部人士 Iqbal J. Hussain 在 2 月 2 日的交易中出售了 38,951 股該公司的股票。這些股票以平均價格 25.15 美元出售，總價值為 979,617.65 美元。交易完成後，內部人士持有 57,645 股公司股票，價值為 1,449,771.75 美元。這筆交易代表了他們持股的 40.32% 的減少。該出售的 SEC 備案提供了更多信息。在過去 90 天內，內部人士出售了 349,073 股公司股票，價值為 9,429,412 美元。當前 7.09% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. TD Waterhouse Canada Inc. bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company's stock worth $39,000 after acquiring an additional 1,516 shares in the last quarter. Wells Fargo &amp; Company MN raised its holdings in shares of Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo &amp; Company MN now owns 3,387 shares of the company's stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr purchased a new position in Centessa Pharmaceuticals during the fourth quarter worth $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近買賣了該公司的股票。TD Waterhouse Canada Inc.在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 25,000 美元。Caitong International Asset Management Co. Ltd 在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值約為 36,000 美元。T. Rowe Price Investment Management Inc.在第四季度將其在 Centessa Pharmaceuticals 的持股增加了 7,580.0%。T. Rowe Price Investment Management Inc.現在擁有 1,536 股該公司的股票，價值 39,000 美元，此前在上個季度又購買了 1,516 股。Wells Fargo &amp; Company MN 在第四季度將其在 Centessa Pharmaceuticals 的持股增加了 42.4%。Wells Fargo &amp; Company MN 現在擁有 3,387 股該公司的股票，價值 85,000 美元，此前在上個季度又購買了 1,008 股。最後，Knott David M Jr 在第四季度購買了 Centessa Pharmaceuticals 的新股份，價值 100,000 美元。82.01% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Centessa Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Centessa Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&amp;D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.</p>
<div class="lb-trans"><p>Centessa Pharmaceuticals plc 是一家全球臨牀階段生物製藥公司，專注於在多個疾病領域發現和開發創新療法。該公司運營一個模塊化的研發網絡，將一系列獨立的專業研究實體整合在一個企業框架下。該結構旨在加速決策和資源分配，同時利用每個治療領域的深厚科學專業知識。</p>
</div><p>Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.</p>
<div class="lb-trans"><p>Centessa 的產品線涵蓋腫瘤學、免疫學、神經科學、心血管和代謝疾病，以及罕見遺傳疾病。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Centessa Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Centessa Pharmaceuticals</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q05UQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CNTA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Centessa Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Centessa Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Centessa Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Centessa Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Centessa Pharmaceuticals 並不在名單上。</p>
</div><p>While Centessa Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Centessa Pharmaceuticals 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Centessa Pharmaceuticals' (CNTA) Equal Weight Rating Reaffirmed at Wells Fargo & Company

Market Beat

Centessa Pharmaceuticals

富國銀行

Toronto Dominion Bank

普信金融

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

富國銀行公司重申了對 Centessa Pharmaceuticals（CNTA）的持平評級